Medistim (MEDI)

TekBot · januar 31, 2025, 9:03am

Medistim strengthens its Commercial Operations

(Oslo, 31 January 2025) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway. Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery.

Today, the company announces the strengthening of its commercial operations with the appointment of Mr. Mike Karim as Chief Commercial Officer (CCO), reporting to the President and CEO. Mr. Karim brings deep industry expertise, strategic insight, and a proven track record from leadership roles at esteemed companies such as Boston Scientific, Lombard Medical, HeartWare, and Oxford Endovascular, with a focus on the cardiac and vascular fields. With a strong foundation in sales, he has led Sales, Marketing, and General Management functions, successfully driving growth in international markets.
…

Vis børsmeldingen

Furthermore, leadership of Medistim’s AMERICAS sales region—including its largest current market and greatest growth opportunity, the USA—has been entrusted to Mr. Tony Winter. Mr. Winter brings extensive commercial leadership experience across the cardiac, vascular, interventional, and surgical sectors. With more than a decade at Medtronic, contributions to Synovis Life Technologies, and most recently, leadership of the U.S. sales organization at ACIST Medical Systems, he is well-positioned to drive Medistim’s continued expansion in the region.

“Medistim stands at a pivotal moment as we enter 2025, poised for significant growth driven by the launch of the INTUI software platform, which is advancing innovation in the Cardiac segment, and a focused strategy in the Vascular segment, supported by the PATENT study and our commitment to advancing Peripheral Bypass,” says Medistim President and CEO Kari E. Krogstad. “This is the perfect time to strengthen our commercial efforts. With these strategic additions to our team, enhanced commercial initiatives, and a focus on fostering collaboration and sharing best practices across all regions, I am confident we will accelerate growth throughout this year and beyond.”

In his CCO role, Mr. Karim will lead and support the efforts of Tony Winter (AMERICAS), Stephanie Stenhagen (EMEA), and Roger Morberg (APAC) as they continue driving Medistim’s growth and success.

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth over the past 20 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Canada, China, Germany, UK, Spain, Denmark, Sweden and Norway, in addition to more than 60 distributors in Europe, Asia, Middle East, Africa, and South America. For more information, visit the Medistim home page: www.medistim.com

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

Savepig · februar 2, 2025, 6:28pm

Føler det straks er på tide å kjøpe her altså

zzimba · februar 10, 2025, 10:52pm

Kun basert på teknisk? De driver med fornuftige ting også? Veldig illikvid aksje

Savepig · februar 18, 2025, 8:59am

Ja ser kun på teknisk i Medistim, er ikke oppdatert på det fundamendale. Den ser fortsatt veldig lovende ut

Se etter etablert brudd over 50 dagers snitt og senere golden cross 50/200

TekBot · februar 24, 2025, 12:50pm

Fourth quarter results and preliminary financials for 2024 for Medistim ASA

TekBot · februar 28, 2025, 7:56am

Results for the fourth quarter and preliminary financial results for Medistim for 2024

All time high quarter for sales revenues, ending at MNOK 151.1, 11.4% above fourth quarter last year (MNOK 135.6). Full year sales ended at MNOK 562.6, 6.9% above last year (MNOK 526.4).

Currency neutral sales of own products was up 9.7% for the quarter and 3.9% for the full year.
…

Vis børsmeldingen

Recurring sales remained high at 71.5% (71.3%) for the quarter and 73.7% (69.3%) for the year.

AMERICAS delivered a strong quarter with 29.7% currency neutral growth. EMEA showed strong performance with currency neutral growth of 10.9%. APAC was down 24.4% for the quarter.

Operating profit (EBIT) for the quarter ended at MNOK 25.8 giving a 17.1% EBIT margin (MNOK 22.3, a 16.4% margin). For the full year, EBIT was at MNOK 131,1 (MNOK 131.4) giving a 23.3% EBIT margin (25.0%).

Third-party distributor sales in Scandinavia increased 10.4% for the quarter and 13.1% for the year.

In December, Medistim launched its new MiraQ INTUI software platform for Cardiac surgery.

For vascular surgery, Medistim launched a multicenter study of TTFM and HFUS imaging as completion control in peripheral bypass.

Solid cash position at quarter end with MNOK 179.2 and no interest-bearing debt. The Board of Directors suggests a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.8 (MNOK 82.4).

Kilde

TekBot · mars 4, 2025, 1:23pm

NOTIFICATION OF TRADE IN MEDISTIM ASA

Savepig · mars 10, 2025, 1:41pm

Eksemplarisk brudd opp fra nedtrend i Medistim

TekBot · mars 11, 2025, 7:00am

Medistim ASA – Initiation of share buy-back programme

Oslo, 11 March 2025: The Board of Directors of Medistim ASA (“Medistim” or “the Company”) has resolved to initiate a share buyback program. The share buyback program will be executed in accordance with the authorization granted to the Board of Directors by the Annual General Meeting of Medistim held on 24 April 2024.

The share buyback program will commence on 11 March 2025 and end no later than 7 May 2025, the last trading day prior to the Company’s 2025 Annual General Meeting. The share buyback program covers purchases of up to 70,000 shares, equivalent to approximately 0.38% of the Company’s current share capital, with a maximum consideration of NOK 35,000,000. Shares repurchased under the program will be used in connection with the Company’s long-term share-based incentive plan for senior management.
…

Vis børsmeldingen

Medistim has engaged DNB Markets, a part of DNB Bank ASA, to manage and carry out the share repurchases in the market. DNB Markets will make its trading decisions independently of, and uninfluenced by Medistim.

The share buyback program will be carried out in accordance with Regulation (EU) No 596/2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) No 2016/1052 (the “Safe Harbour Regulation”).

The Company reserves the right to make subsequent changes to the above terms for the program and will in such case make appropriate announcements in this respect.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

Kilde

TekBot · mars 17, 2025, 7:01am

Medistim ASA – Status on share buyback

Oslo, 17th of March 2025: Reference is made to the stock exchange announcement made by Medistim ASA on 11 March 2025 of the launch of Medistim’s program to repurchase up to 70,000 of the Company’s shares in open market transactions for a total amount of up to NOK 35,000,000 during the period from 11 March 2025, until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For the period from and including 11 March 2025, through14th of March 2025, the Company purchased a total of 14,000 shares at an average price of NOK 189.0167 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

…

Vis børsmeldingen

Date: 11 mars 2025. Number of share: 5000. Avg price: NOK 189.2370 per share
Date: 12 mars 2025. Number of share: 4000. Avg price: NOK 190.8628 per share
Date: 13 mars 2025. Number of share: 2279. Avg price: NOK 188.7749 per share
Date: 14 mars 2025. Number of share: 2721. Avg price: NOK 186.1009 per share

Total for the period 14,000 shares was purchased at average share share price of NOK 189.0167 per share. Total transaction value was NOK 2,646,234.75.

The issuer’s holding of own shares:
Following the completion of the above transactions, Medistim owns a total of 37,117 of own shares (including 23,117 shares owned prior to the launch of the buyback program), corresponding to 0.202 % of Medistim’s share capital.

Appendix:
An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mars 21, 2025, 4:01pm

Medistim ASA – Status on share buyback

Oslo, 21st of March 2025: Reference is made to the stock exchange announcement made by Medistim ASA on 11 March 2025 of the launch of Medistim’s program to repurchase up to 70,000 of the Company’s shares in open market transactions for a total amount of up to NOK 35,000,000 during the period from 11 March 2025, until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For the period from and including 11 March 2025, through 21st of March 2025, the Company purchased a total of 27,543 shares at an average price of NOK 187.9479 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

…

Vis børsmeldingen

Date / Aggregated daily volume (#shares) / Weighted average share price per day (NOK) / Total daily transaction value (NOK)

Date: 17 mars 2025. Number of share: 1479. Avg price: NOK 189.4561 per share
Date: 18 mars 2025. Number of share: 2564. Avg price: NOK 187.0456 per share
Date: 19 mars 2025. Number of share: 3500. Avg price: NOK 186.6269 per share
Date: 20 mars 2025. Number of share: 3000. Avg price: NOK 186.8238 per share
Date: 21 mars 2025. Number of share: 3000. Avg price: NOK 185.6533 per share

Total for this period:
13,543 shares purchased at average share price of NOK 186.8430 per share. Total transaction value was NOK 2,530,415.94.

Previously disclosed buybacks under the program:
14,000 shares purchased at average share price of NOK 189.0167 per share. Total transaction value was NOK 2,646,234.75

The issuer’s holding of own shares:
Following the completion of the above transactions, Medistim owns a total of 50,660 of own shares (including 23,117 shares owned prior to the launch of the buyback program), corresponding to 0.276 % of Medistim’s share capital.

Appendix:
An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mars 28, 2025, 4:54pm

Medistim ASA – Status on share buyback

Oslo, 28th of March 2025: Reference is made to the stock exchange announcement made by Medistim ASA on 11 March 2025 of the launch of Medistim’s program to repurchase up to 70,000 of the Company’s shares in open market transactions for a total amount of up to NOK 35,000,000 during the period from 11 March 2025, until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For the period from and including 11 March 2025, through 28th of March 2025, the Company purchased a total of 42,543 shares at an average price of NOK 186.1431 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

…

Vis børsmeldingen

Date / Aggregated daily volume (#shares) / Weighted average share price per day (NOK) / Total daily transaction value (NOK)

Date: 24 mars 2025. Number of share: 3,000. Avg price: NOK 186.6598 per share
Date: 25 mars 2025. Number of share: 3,000. Avg price: NOK 186.7532 per share
Date: 26 mars 2025. Number of share: 3,000. Avg price: NOK 183.0003 per share
Date: 27 mars 2025. Number of share: 3,000. Avg price: NOK 179.2613 per share
Date: 28 mars 2025. Number of share: 3,000. Avg price: NOK 178.4685 per share

Total for this period:
15,000 shares purchased at average share price of NOK 182.8290 per share. Total transaction value was NOK 2,742,435.30.

Previously disclosed buybacks under the program:
27,543 shares purchased at average share price of NOK 187.9309 per share. Total transaction value was NOK 5,176,183.41

The issuer’s holding of own shares:
Following the completion of the above transactions, Medistim owns a total of 65,660 of own shares (including 23,117 shares owned prior to the launch of the buyback program), corresponding to 0.358 % of Medistim’s share capital.

Appendix:
An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 2, 2025, 8:55am

Medistim ASA – Status on share buyback - Correction

In the notification of trade from Medistim ASA the 28th of March the attachment with the overview of all the transactions under the program was missing. Attached is the overview of all transaction under the program as of the 28th of March.

…

Vis børsmeldingen

Oslo, 28th of March 2025: Reference is made to the stock exchange announcement made by Medistim ASA on 11 March 2025 of the launch of Medistim’s program to repurchase up to 70,000 of the Company’s shares in open market transactions for a total amount of up to NOK 35,000,000 during the period from 11 March 2025, until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For the period from and including 11 March 2025, through 28th of March 2025, the Company purchased a total of 42,543 shares at an average price of NOK 186.1431 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

Date / Aggregated daily volume (#shares) / Weighted average share price per day (NOK) / Total daily transaction value (NOK)

Date: 24 mars 2025. Number of share: 3,000. Avg price: NOK 186.6598 per share
Date: 25 mars 2025. Number of share: 3,000. Avg price: NOK 186.7532 per share
Date: 26 mars 2025. Number of share: 3,000. Avg price: NOK 183.0003 per share
Date: 27 mars 2025. Number of share: 3,000. Avg price: NOK 179.2613 per share
Date: 28 mars 2025. Number of share: 3,000. Avg price: NOK 178.4685 per share

Total for this period:
15,000 shares purchased at average share price of NOK 182.8290 per share. Total transaction value was NOK 2,742,435.30.

Previously disclosed buybacks under the program:
27,543 shares purchased at average share price of NOK 187.9309 per share. Total transaction value was NOK 5,176,183.41

The issuer’s holding of own shares:
Following the completion of the above transactions, Medistim owns a total of 65,660 of own shares (including 23,117 shares owned prior to the launch of the buyback program), corresponding to 0.358 % of Medistim’s share capital.

Appendix:
An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 2, 2025, 12:07pm

Medistim ASA – Status on share buy back and correct attachment

TekBot · april 4, 2025, 4:05pm

Medistim ASA – Status on share buyback

Oslo, 4th of April 2025: Reference is made to the stock exchange announcement made by Medistim ASA on 11 March 2025 of the launch of Medistim’s program to repurchase up to 70,000 of the Company’s shares in open market transactions for a total amount of up to NOK 35,000,000 during the period from 11 March 2025, until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For the period from and including 11 March 2025, through 4th of April 2025, the Company purchased a total of 52,181 shares at an average price of NOK 183.8225 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

…

Vis børsmeldingen

Date / Aggregated daily volume (#shares) / Weighted average share price per day (NOK) / Total daily transaction value (NOK)

Date: 31 March 2025. Number of share: 3,000. Avg price: NOK 172.3090 per share
Date: 1 April 2025. Number of share: 2,000. Avg price: NOK 177.1560 per share
Date: 2 April 2025. Number of share: 2,000. Avg price: NOK 177.0038 per share
Date: 3 April 2025. Number of share: 2,000. Avg price: NOK 171.1533 per share
Date: 4 April 2025. Number of share: 638. Avg price: NOK 165.2147 per share

Total for this period:
9,638 shares purchased at average share price of NOK 172.5674 per share. Total transaction value was NOK 1,672,960.18.

Previously disclosed buybacks under the program:
42,543 shares purchased at average share price of NOK 186.1431 per share. Total transaction value was NOK 7,919,085.99

The issuer’s holding of own shares:
Following the completion of the above transactions, Medistim owns a total of 75,298 of own shares (including 23,117 shares owned prior to the launch of the buyback program), corresponding to 0.411 % of Medistim’s share capital.

Appendix:
An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 8, 2025, 2:19pm

Board approval of the 2024 Financial statements for Medistim ASA

(Oslo, 8th of April 2025) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarter in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
…

Vis børsmeldingen

surgery, announces that the Board of Medistim ASA has approved the Financial
Statements for 2024. The Financial Statements are without changes from the
preliminary Financial Statements published on the 28th of February 2025. The
annual report for 2024 is now available. The Annual General Meeting will be held
on 8th of May 2025.

About Medistim:
Medistim was established in 1984, and has a track record of profitable growth
over the past >15 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,
Canada, China, Sweden and Norway, in addition to the about 60 distributors in
Europe, Asia, Middle East, Africa, and South America. For more information,
visit the Medistim home page: www.Medistim.com

This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

TekBot · april 10, 2025, 7:56am

Notice of Annual General Meeting in Medistim ASA

(Oslo, 10th of April 2025) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarters in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
…

Vis børsmeldingen

surgery, announces the Annual General Meeting for the company.

The Annual General Meeting will take place on the 8th of May 2025 at 10.00
and is held at Medistim’s offices at Økernveien 94 in Oslo. Attached are the
agenda for the meeting, the voting form and the annual report for 2024. It is
possible to give proxy with and without voting instructions. By using a proxy
with voting instructions, the shareholders will vote on the specific issues
without personal attendance. For further information on the use of proxy, see
general information at the bottom of the notice and enclosed proxy forms.

Attached is also the annual report for 2024 for Medistim ASA in PDF format and
in ESEF format. The report is also available on the company web site:
www.medistim.com.

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past >15 years. The company is a pioneer within its segment, and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, UK,
Spain, Denmark, Sweden and Norway, in addition to the about 60 distributors in
Europe, Asia, Middle East, Africa, Canada and South America. For more
information, visit the Medistim home page: www.Medistim.com
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act (Verdipapirhandelloven).

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

TekBot · april 11, 2025, 4:23pm

Medistim ASA – Status on share buyback

Oslo, 411h of April 2025: Reference is made to the stock exchange announcement made by Medistim ASA on 11 March 2025 of the launch of Medistim’s program to repurchase up to 70,000 of the Company’s shares in open market transactions for a total amount of up to NOK 35,000,000 during the period from 11 March 2025, until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For the period from and including 11 March 2025, through 11th of April 2025, the Company purchased a total of 61,382 shares at an average price of NOK 180.9973 per share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please find below the transaction overview:

…

Vis børsmeldingen

Date / Aggregated daily volume (#shares) / Weighted average share price per day (NOK) / Total daily transaction value (NOK)

Date: 7 April 2025. Number of share: 2,000. Avg price: NOK 157.9910 per share
Date: 8 April 2025. Number of share: 2,000. Avg price: NOK 168.9735 per share
Date: 9 April 2025. Number of share: 1,505. Avg price: NOK 166.3548 per share
Date: 10 April 2025. Number of share: 1,890. Avg price: NOK 169.7450 per share
Date: 11 April 2025. Number of share: 1,806. Avg price: NOK 162.1384 per share

Total for this period:
9,201 shares purchased at average share price of NOK 164.9748 per share. Total transaction value was NOK 1,517,932.97.

Previously disclosed buybacks under the program:
52,181 shares purchased at average share price of NOK 183.8225 per share. Total transaction value was NOK 9,592,046.16

The issuer’s holding of own shares:
Following the completion of the above transactions, Medistim owns a total of 84,499 of own shares (including 23,117 shares owned prior to the launch of the buyback program), corresponding to 0.461 % of Medistim’s share capital.

Appendix:
An overview of all transactions made under the buyback program that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 15, 2025, 3:56pm

Dividend proposal for 2024 Medistim ASA - Key information

TekBot · april 16, 2025, 9:29am

Medistim (MEDI)

Medistim strengthens its Commercial Operations

Fourth quarter results and preliminary financials for 2024 for Medistim ASA

Results for the fourth quarter and preliminary financial results for Medistim for 2024

NOTIFICATION OF TRADE IN MEDISTIM ASA

Medistim ASA – Initiation of share buy-back programme

Medistim ASA – Status on share buyback

Medistim ASA – Status on share buyback

Medistim ASA – Status on share buyback

Medistim ASA – Status on share buyback - Correction

Medistim ASA – Status on share buy back and correct attachment

Medistim ASA – Status on share buyback

Board approval of the 2024 Financial statements for Medistim ASA

Notice of Annual General Meeting in Medistim ASA

Medistim ASA – Status on share buyback

Dividend proposal for 2024 Medistim ASA - Key information

Dividend proposal for 2024 Medistim ASA - Key information - Correction of record date